Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Trial to Test Effect of Rivaroxaban or Apixaban on Menstrual Blood Loss in Women (RAMBLE)

Trial Profile

Randomized Trial to Test Effect of Rivaroxaban or Apixaban on Menstrual Blood Loss in Women (RAMBLE)

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 17 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary) ; Rivaroxaban
  • Indications Venous thromboembolism
  • Focus Adverse reactions
  • Acronyms RAMBLE

Most Recent Events

  • 18 Apr 2023 Status changed from recruiting to completed.
  • 18 Apr 2023 Status changed from recruiting to completed.
  • 04 Dec 2019 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top